Price movement over the last 24 hours
ARK Genomic Revolution ETF vs Health Care Select Sector SPDR Fund — how do they compare? ARK Genomic Revolution ETF trades at $41.21, while Health Care Select Sector SPDR Fund trades at $161.02. Which is the better fit depends on your goals.
| ARKG | XLV | |
|---|---|---|
Sector | Sector/Thematic | — |
52-Week High | $43.57 | $164.48 |
52-Week Low | $23.09 | $129.01 |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
XLV trades at $160.84, down 0.82% with a bullish technical signal from moving averages. The healthcare ETF shows defensive characteristics amid market volatility, with recent news highlighting its stability versus biotech alternatives. Technical indicators show mixed signals with RSI at neutral levels while ADX indicates strong trend momentum.
Healthcare sector rotation provides support as investors seek defensive exposure. Key risks include patent cliff concerns and regulatory pressures, while innovation in medical technology offers growth potential. The ETF's diversification across 59 healthcare names provides stability compared to concentrated biotech funds.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →